Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: A randomized, double-blind, placebo-controlled European study

Journal of Infection

Volumn 40, Issue 1, 2000, Pages 42-48

  Makela M J ^a   Pauksens, K ^b   Rostila, T ^c   Fleming, D M ^d   Man, C Y ^e   Keene, O N ^e   Webster, A ^e  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Aurora Hospital   (Finland)

^d Northfield Health Centre   (United Kingdom)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SIALIDASE INHIBITOR; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; HIGH RISK PATIENT; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PHARYNGITIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINUSITIS; VOMITING;

EID: 0343851036     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.1999.0602     Document Type: Article

References (25)

1. Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics. 9 (Suppl 3):1996;62-66.
2. Schoenbaum S. C. Economic impact of influenza. The individual's perspective. Am J Med. 82:1987;26-30.
3. Monto A. S. Influenza: quantifying morbidity and mortality. Am J Med. 82:1987;20-25.
4. Nicholson K. G. Clinical features of influenza. Semin Respir Infect. 17:1992;26-37.
5. MMWR Morb Mortal Wkly Rep. 47 (RR-6):1998;1-26.
6. Palache A. M. Influenza vaccines. A reappraisal of their use. Drugs. 54:1997;841-856.
7. Hayden F. G. Amantadine and rimantadine resistance in influenza A viruses. Curr Opin Infect Dis. 7:1994;674-677.
8. Belshe R. B., Burk B., Newman F., Cerruti R. L., Sim I. S. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis. 159:1989;430-435.
9. Nicholson K. G., Wiselka M. J. Amantadine for influenza A. Br Med J. 302:1991;425-426.
10. Woods J. M., Bethell R. C., Coates J. A. V. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother. 37:1993;1473-1479.
11. von Itzstein M., Wu W. Y., Kok G. B. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363:1993;418-423.
12. Liu C., Air G. M. Selection and characterization of a neuraminidase-minus mutant of influenza virus and its rescue by cloned neuraminidase genes. Virology. 194:1993;403-407.
13. Colman P. M. Neuraminidase: enzyme and antigen. Krug R. M. The Influenza Viruses. 1989;175-218 Plenum Press, New York.
14. Hayden F. G., Rollins B. S., Madren L. K. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res. 25:1994;123-131.
15. Ryan D. M., Ticehurst J., Dempsey M. H., Penn C. R. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother. 38:1994;2270-2275.
16. Hayden F. G., Treanor J. J., Betts R. F., Lobo M., Esinhart J. D., Hussey E. K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J Am Med Assoc. 275:1996;295-299.
17. Hayden F. G., Lobo M., Hussey E. K., Eason C. U. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. Brown L. E., Hampson A. W., Webster R. G. Options for the Control of Influenza III. 1996;718-725 Elsevier Science, BV.
18. Hayden F. G., Osterhaus A. D. M. E., Treanor J. J. Efficacy and safety of the neuramindiase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med. 337:1997;874-880.
19. Barnett J., Dempsey M., Tisdale M., Rothbarth P., de Groot R., Osterhaus A. D. M. E. Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir (GG167) during phase II clinical efficacy trials [abstract]. Toronto, Canada. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 230:1997.
20. Osterhaus A. D. M. E., Tisdale M., Elliott M. A double blind randomised trial of zanamivir in the treatment of acute influenza - clinical and virological efficacy results [abstract]. San Diego, California, USA: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 11:1998.
21. Ellis J. S., Fleming D. M., Zambon M. C. Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J Clin Microbiol. 35:1997;2076-2082.
22. Noether G. E. Sample size determination for some common nonparametric tests. J Am Stat Assoc. 82:1987;645-647.
23. Lehmann, E. L. Nonparametrics: Statistical Methods Based on Ranks, San Francisco, Holden-Day, 1975.
24. Efron, B. Tibshirani, R. J. An Introduction to the Bootstrap, New York, Chapman Hall, 1993, 178, 201, 398, 412.
25. Lancet. 352:1998;1877-1881.